Karnofsky and ECOG performance status scoring in lung cancer: A prospective, longitudinal study of 536 patients from a single institution
- 30 June 1996
- journal article
- research article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 32 (7), 1135-1141
- https://doi.org/10.1016/0959-8049(95)00664-8
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Symptomatic, stage IV, non-small-cell lung cancer (NSCLC): response, toxicity, performance status change and symptom relief in patients treated with cisplatin, vinblastine and mitomycin-CCancer Chemotherapy and Pharmacology, 1995
- A randomised trial of MACC chemotherapy with or without lonidamine in advanced non-small cell lung cancerEuropean Journal of Cancer, 1994
- Prognostic factors in lung cancer: tables and commentsEuropean Respiratory Journal, 1994
- A phase II study of methotrexate, doxorubicin, cyclophosphamide, and lomustine chemotherapy and lonidamine in advanced non-small cell lung cancerCancer, 1993
- Can Karnofsky performance status be transformed to the Eastern Cooperative Oncology Group scoring scale and vice versa?European Journal of Cancer, 1992
- Imaging lung cancer by scintigraphy with indium 111-labeled F(ab')2 fragments of the anticarcinoembryonic antigen monoclonal antibody F023C5Cancer, 1992
- Performance and prognosis in patients with lung cancer. The Edinburgh Lung Cancer Group.Thorax, 1990
- Tumor markers in bronchogenic carcinoma. Superiority of tissue polypeptide antigen to carcinoembryonic antigen and carbohydrate antigenic determinant 19-9Cancer, 1987
- Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramideJournal of Chronic Diseases, 1960
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958